HANSOH PHARMA (03692): All approved indications of its marketed innovative drugs have been included in the medical insurance catalog.
HANSOH PHARMA (03692) announced that one additional indication for the Group's innovative drug Ameile and two additional indications for Xinyue have been successfully included in the new edition of the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026). The new national catalog will be officially implemented on January 1, 2027.
HANSOH PHARMA (03692) announced that the group's innovative drug Amelox has added one new indication and Xinyue has added two new indications, which have been successfully included in the new edition of the "National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2026)". The new national catalog will be officially implemented on January 1, 2027.
In addition, the remaining four indications of the group's innovative drug almonertinib mesylate tablets (trade name: Amelox), the remaining one indication of inebilizumab injection (trade name: Xinyue), and flumatinib mesylate tablets (trade name: Hansoh Xinfu) have all been renewed for inclusion in the 2026 National Medical Insurance Catalog; pegylated loxenatide injection (trade name: Fulimei) has been renewed for inclusion in the 2026 National Medical Insurance Catalog with an expanded medical insurance payment scope; pemivibart injection (trade name: Shengluolai) and tenofovir amibufenamide tablets (trade name: Hengmu) are currently still within the agreement period of the National Medical Insurance Catalog, with the agreement valid until December 31, 2027; morinidazole and sodium chloride injection (trade name: Mailinda) has been included in Category B of the National Medical Insurance Routine Catalog. All approved indications of the group's marketed innovative drugs have been included in the medical insurance catalog, which helps to further improve the affordability and accessibility of each innovative drug among patients.
Related Articles

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.
GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.






